ARCHIVES

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Targeting One Specific Protein Can Double PFS; Triple Overall Survival

May 27, 2011

NCCAM Awards To Establish Two Cancer Research Centers.

October 13, 2000

Funding opportunities listed.

November 12, 2004

Opdivo Study Shows 41 Percent One-Year Survival In Patients With at Least Two Past Therapies

November 28, 2014

Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent

January 8, 1982

ASCO Members asked To Help In Planning

August 26, 1988